Related Experiment Videos
The Myocardial Ischemia Reduction with Acute Cholesterol Lowering (MIRACL) trial: a new frontier for statins?
David Waters1, Gregory G Schwartz, Anders G Olsson
1Division of Cardiology, Room 5G1, San Francisco General Hospital, 1001 Potrero Avenue, San Francisco, CA 94110, USA. dwaters@medsfgh.ucsf.edu
Insights
Early intensive cholesterol lowering with atorvastatin significantly reduced major adverse cardiac events in patients following acute coronary syndrome. This treatment, initiated in-hospital, benefits patients regardless of their baseline cholesterol levels.
Area of Science:
- Cardiology
- Clinical Trials
- Pharmacology
Background:
- Acute coronary syndrome (ACS) is a critical cardiovascular event.
- Effective lipid-lowering strategies are essential for secondary prevention post-ACS.
Purpose of the Study:
- To evaluate the efficacy of intensive cholesterol lowering with atorvastatin in reducing adverse cardiovascular outcomes within 4 months after ACS.
- To determine if early initiation of atorvastatin impacts the composite endpoint of cardiovascular death, nonfatal myocardial infarction, cardiac arrest, or recurrent ischemia.
Main Methods:
- The Myocardial Ischemia Reduction with Acute Cholesterol Lowering (MIRACL) trial enrolled 3086 patients.
- Participants received atorvastatin 80 mg/day initiated 24-96 hours after ACS.
- Outcomes were assessed over a 4-month period.
Main Results:
- The primary composite endpoint was significantly reduced from 17.4% to 14.8% (P = 0.048).
- This reduction was observed in patients treated with early-onset, high-intensity atorvastatin therapy.
Conclusions:
- Early initiation of intensive cholesterol lowering with atorvastatin (80 mg/day) is beneficial for patients with acute coronary syndromes.
- Treatment should be considered before hospital discharge, irrespective of baseline LDL-cholesterol levels.
Abstract:
The Myocardial Ischemia Reduction with Acute Cholesterol Lowering (MIRACL) Trial tested the hypothesis that intensive lowering of cholesterol with atorvastatin (80 mg/day) initiated 24-96 h after an acute coronary syndrome would, over 4 months, reduce the incidence of the composite endpoint of death, nonfatal infarction, resuscitated cardiac arrest, and recurrent symptomatic myocardial ischemia with new objective symptoms requiring emergency rehospitalization. This primary composite endpoint was reduced from 17.4% to 14.8% (P = 0.048) among the 3086 patients enrolled. The results of MIRACL suggest that patients with acute coronary syndromes should begin to receive this treatment before leaving hospital, irrespective of baseline levels of low-density lipoprotein-cholesterol.